JiscMail Logo
Email discussion lists for the UK Education and Research communities

Help for CCP4BB Archives


CCP4BB Archives

CCP4BB Archives


CCP4BB@JISCMAIL.AC.UK


View:

Message:

[

First

|

Previous

|

Next

|

Last

]

By Topic:

[

First

|

Previous

|

Next

|

Last

]

By Author:

[

First

|

Previous

|

Next

|

Last

]

Font:

Proportional Font

LISTSERV Archives

LISTSERV Archives

CCP4BB Home

CCP4BB Home

CCP4BB  January 2013

CCP4BB January 2013

Options

Subscribe or Unsubscribe

Subscribe or Unsubscribe

Log In

Log In

Get Password

Get Password

Subject:

Re: About NCS and inhibitors

From:

Ethan Merritt <[log in to unmask]>

Reply-To:

Ethan Merritt <[log in to unmask]>

Date:

Mon, 7 Jan 2013 12:50:14 -0800

Content-Type:

Text/Plain

Parts/Attachments:

Parts/Attachments

Text/Plain (157 lines)

On Monday, January 07, 2013 12:10:17 pm Edward A. Berry wrote:
> The idea is (whether it's valid or not) to apply the information from
> both sites simultaneously. If the density is pretty ambiguous and one side
> tends to drift off into an alternate conformation and the other drifts off
> into another conformation, but you have every reason to believe that
> the conformation is the same on both sides, applying NCS allows you to
> refine a single conformation that is consistent with both.

Ah, but what if you don't have every reason to believe
that the conformation is the same on both sides?

> More generally, is there any reason to not? I suppose ligands
> may be more likely than amino acids to violate NCS, but good
> practices would say examine each residue for violations.
>
> You could say, why enforce NCS on the 27'th residue of each chain, since
> their contribution to the number of parameters is small.
> (mind you,there may be good reasons to not constrain ligands
> that I m not aware of, if so I hope someone speak up)

The example mentioned earlier was HIV protease (a homodimer) in complex
with an asymmetric inhitor. I.e. a single asymmetric ligand occupying a
single site formed by 2 NCS-related chains.  Depending on what treatment
of NCS is available, it may or may not be reasonable to apply NCS
restraints to the protein.  Local geometry restraints may be
reasonable but coordinate restraints probably not.

In practice you would normally expect the ligand to be stochastically
present in one of 2 orientations, corresponding to the 2-fold NCS.
But if the ligand is not totally enclosed by the protein, the two
orientations may not be equally present and indeed might conceivably
not follow the overall 2-fold NCS of the protein.

To bring in an example that I've worked on myself, the cholera toxin
B-pentamer has 5 identical receptor binding sites related by 5-fold
NCS.  Small-molecule receptor analogs bound at those sites can extend well
beyond the protein envelope; their precise binding conformation is
affected by lattice contacts that obviously don't follow 5-fold NCS.
This is a case where applying the protein NCS to the ligands
would not make sense.


	Ethan



>
> eab
>
> Boaz Shaanan wrote:
> > Just a naive question: why apply NCS to ligands at all? Their contribution to the number of parameters and hence to the param/obs ratio, the main argument for applying NCS, is negligible, isn't it?
> >
> >   Boaz
> >
> > Boaz Shaanan, Ph.D.
> > Dept. of Life Sciences
> > Ben-Gurion University of the Negev
> > Beer-Sheva 84105
> > Israel
> >
> > E-mail: [log in to unmask]
> > Phone: 972-8-647-2220  Skype: boaz.shaanan
> > Fax:   972-8-647-2992 or 972-8-646-1710
> >
> >
> >
> >
> >
> > ________________________________________
> > From: CCP4 bulletin board [[log in to unmask]] on behalf of Edward A. Berry [[log in to unmask]]
> > Sent: Monday, January 07, 2013 6:12 PM
> > To: [log in to unmask]
> > Subject: Re: [ccp4bb] About NCS and inhibitors
> >
> > But I think the original poster meant partially overlapped after applying
> > the ncs- operator- i.e. they are not ncs related but occupy partly the same
> > position (in the two non-overlapping copies of the binding site).
> >
> > Then I guess it depends how clear the density is- If the density is not very
> > clear and if the protein residues of the active site do follow ncs, I would try
> > rebuilding ligand b to match a and (separately) a to match b and refining
> > with ncs applied to the ligand; and see if the resulting fit looks just as good.
> > eab
> >
> > Joel Sussman wrote:
> >> Dear All,
> >> Something like what Felix wrote is seen in the crystal structure of *recombinant human acetylcholinesterase* (*rhAChE*)
> >> (PDB-ID: *3lii*), with two molecules are seen in the asymmetric unit.
> >> * In one molecule, the active-site gorge (where inhibitors normally lie) is occupied with part of a peptide loop from a
> >> symmetrically related rhAChE.
> >> * While the corresponding region of the other copy of rhAChE is void of this peptide.
> >> See figs 15-16 in:
> >> Dvir, H., Silman, I., Harel, M., Rosenberry, T. L.&  Sussman, J. L. (2010). "Acetylcholinesterase: From 3D structure to
> >> function" /Chemico-Biological Interactions/ *187*, 10-22.
> >> * So, in essence, no reason to ever assume that two copies in asymmetric unit will be identical, or have identical
> >> inhibitors bound, or 'surrogate inhibitors' (like in this case) bound. Sometimes differences are due to difference in
> >> crystal packing
> >> Best regards,
> >> Joel
> >>
> >>
> >> On 7 Jan 2013, at 11:58, Felix Frolow wrote:
> >>
> >>> I apologise for typing blinbly:
> >>> " if one is in, the second can't be"
> >>> FF
> >>> Dr Felix Frolow
> >>> Professor of Structural Biology and Biotechnology, Department of Molecular Microbiology and Biotechnology
> >>> Tel Aviv University 69978, Israel
> >>>
> >>> Acta Crystallographica F, co-editor
> >>>
> >>> e-mail: [log in to unmask]<mailto:[log in to unmask]>
> >>> Tel: ++972-3640-8723
> >>> Fax: ++972-3640-9407
> >>> Cellular: 0547 459 608
> >>>
> >>> On Jan 7, 2013, at 11:48 , Felix Frolow<[log in to unmask]<mailto:[log in to unmask]>>  wrote:
> >>>
> >>>> Why not? They can be mutually excluding! If one is in, the second can be. This phenomenon brakes a local symmetry.
> >>>> FF
> >>>>
> >>>> Dr Felix Frolow
> >>>> Professor of Structural Biology and Biotechnology, Department of Molecular Microbiology and Biotechnology
> >>>> Tel Aviv University 69978, Israel
> >>>>
> >>>> Acta Crystallographica F, co-editor
> >>>>
> >>>> e-mail: [log in to unmask]<mailto:[log in to unmask]>
> >>>> Tel: ++972-3640-8723
> >>>> Fax: ++972-3640-9407
> >>>> Cellular: 0547 459 608
> >>>>
> >>>> On Jan 7, 2013, at 11:28 , Xiaopeng Hu<[log in to unmask]<mailto:[log in to unmask]>>  wrote:
> >>>>
> >>>>> Dear All,
> >>>>>
> >>>>> We recently resolved an enzyme/inhibitor complex structure. The enzyme contains two NCS related active site and we
> >>>>> did find extra density in both of them.However we observed that the two inhbitor moleculors are not NCS related, but
> >>>>> partly overlaped if make a NCS moleculor. Has anyone else observed this before? Thanks for any help and suggestion!
> >>>>>
> >>>>>
> >>>>> Best,
> >>>>>
> >>>>> Xiaopeng Hu
> >>>>>
> >>>>
> >>>
> >>
> >
>

--
Ethan A Merritt
Biomolecular Structure Center,  K-428 Health Sciences Bldg
University of Washington, Seattle 98195-7742

Top of Message | Previous Page | Permalink

JiscMail Tools


RSS Feeds and Sharing


Advanced Options


Archives

April 2024
March 2024
February 2024
January 2024
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
March 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
April 2022
March 2022
February 2022
January 2022
December 2021
November 2021
October 2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
December 2020
November 2020
October 2020
September 2020
August 2020
July 2020
June 2020
May 2020
April 2020
March 2020
February 2020
January 2020
December 2019
November 2019
October 2019
September 2019
August 2019
July 2019
June 2019
May 2019
April 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
August 2017
July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007


JiscMail is a Jisc service.

View our service policies at https://www.jiscmail.ac.uk/policyandsecurity/ and Jisc's privacy policy at https://www.jisc.ac.uk/website/privacy-notice

For help and support help@jisc.ac.uk

Secured by F-Secure Anti-Virus CataList Email List Search Powered by the LISTSERV Email List Manager